Skip to main content

The SURPASS trial results

Summarizing efficacy data on tirzepatide, a novel glucose-lowering dual GIP/GLP-1 receptor agonist

What you need to know

The novel type 2 diabetes medication tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.

Its efficacy is being tested in the phase 3 SURPASS clinical trial program, with results of the cardiovascular outcomes study and a trial of tirzepatide in people with obesity but without diabetes expected in 2024. Explore this page for trial results and expert commentary, updated as new results are reported.

SURPASS-1 trial results & series summary

SURPASS-2 trial results

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

SURPASS-3 trial results

SURPASS-4 trial results

SURPASS-5 trial results

At a glance

A quick guide to the SURPASS and SURMOUNT trials

Tirzepatide (formerly known as LY3298176) is a novel glucose-lowering medication that stimulates the receptors for both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1.

View the quick guide here